Education
About Us
Working with TipRanks
Follow Us
Cardiff Oncology, Inc. (CRDF)
NASDAQ:CRDF
Total Valuation
Cardiff Oncology has a market cap or net worth of $127.84M. The enterprise value is $111.20M.
Market Cap$127.84M
Enterprise Value$111.20M
Share Statistics
Cardiff Oncology has 68,364,980 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding68,364,980
Owned by Insiders4.37%
Owned by Institutions2.82%
Financial Efficiency
Cardiff Oncology’s return on equity (ROE) is -1.01 and return on invested capital (ROIC) is -105.93%.
Return on Equity (ROE)-1.01
Return on Assets (ROA)-0.74
Return on Invested Capital (ROIC)-105.93%
Return on Capital Employed (ROCE)-1.08
Revenue Per Employee18.53K
Profits Per Employee-1.43M
Employee Count32
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Cardiff Oncology is ―. Cardiff Oncology’s PEG ratio is 0.15.
PE Ratio―
PS Ratio316.73
PB Ratio4.14
Price to Fair Value4.14
Price to FCF-4.95
Price to Operating Cash Flow-3.26
PEG Ratio0.15
Income Statement
In the last 12 months, Cardiff Oncology had revenue of 593.00K and earned -45.88M in profits. Earnings per share was -0.69.
Revenue593.00K
Gross Profit-311.00K
Operating Income-48.96M
Pretax Income-45.88M
Net Income-45.88M
EBITDA-44.97M
Earnings Per Share (EPS)-0.69
Cash Flow
In the last 12 months, operating cash flow was -37.92M and capital expenditures -44.00K, giving a free cash flow of -37.97M billion.
Operating Cash Flow-37.92M
Free Cash Flow-37.97M
Free Cash Flow per Share-0.56
Dividends & Yields
Cardiff Oncology pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.13
52-Week Price Change-51.80%
50-Day Moving Average2.27
200-Day Moving Average2.58
Relative Strength Index (RSI)48.47
Average Volume (3m)1.47M
Important Dates
Cardiff Oncology upcoming earnings date is Apr 30, 2026, After Close (Confirmed).
Last Earnings DateFeb 24, 2026
Next Earnings DateApr 30, 2026
Ex-Dividend Date―
Financial Position
Cardiff Oncology as a current ratio of 3.67, with Debt / Equity ratio of 1.83%
Current Ratio3.67
Quick Ratio3.67
Debt to Market Cap0.00
Net Debt to EBITDA0.37
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Cardiff Oncology has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Cardiff Oncology EV to EBITDA ratio is -3.81, with an EV/FCF ratio of -4.51.
EV to Sales288.68
EV to EBITDA-3.81
EV to Free Cash Flow-4.51
EV to Operating Cash Flow-4.51
Balance Sheet
Cardiff Oncology has $58.30M in cash and marketable securities with $832.00K in debt, giving a net cash position of $57.47M billion.
Cash & Marketable Securities$58.30M
Total Debt$832.00K
Net Cash$57.47M
Net Cash Per Share$0.84
Tangible Book Value Per Share$0.68
Margins
Gross margin is -1890.39%, with operating margin of -8256.32%, and net profit margin of -7736.26%.
Gross Margin-1890.39%
Operating Margin-8256.32%
Pretax Margin-7736.26%
Net Profit Margin-7736.26%
EBITDA Margin-7583.81%
EBIT Margin-7736.26%
Analyst Forecast
The average price target for Cardiff Oncology is $9.33, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$9.33
Price Target Upside398.93% Upside
Analyst ConsensusStrong Buy
Analyst Count6
Revenue Growth Forecast-27.29%
EPS Growth Forecast16.40%